T2 Biosystems announced that its multi-year capital equipment supplier agreement with Vizient has been extended through March 31, 2025. The products covered under the contract with Vizient include the T2Dx Instrument, the T2Bacteria Panel and the T2Candida Panel, which detect sepsis-causing bacterial and fungal pathogens directly from whole blood. “We are pleased to extend our multi-year agreement with Vizient, the nation’s largest group purchasing organization. This reiterates the continued value that our products offer to patients suspected of sepsis,” stated John Sperzel, Chairman and CEO of T2 Biosystems. “We believe there is a strong need for hospitals to have more effective rapid diagnostics that enable faster targeted therapy and this contract with Vizient improves hospitals’ access to our life-saving technology.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TTOO:
- T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
- T2 Biosystems Anticipates Breakthroughs and Extends NASDAQ Compliance
- T2 Biosystems reiterates 2024 financial outlook
- T2 Biosystems unveils T2Lyme launch plans, business updates
- T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates